Draupnir Bio completes €12 million seed round
Development of oral small molecule degraders of extracellular proteins
Draupnir Bio, a biotechnology company harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular disease-causing proteins, announces equity investments totalling €12 million to support the Company’s ambition to revolutionise the field of targeted protein degradation (TPD).
TPD is a rapidly emerging field in drug development, exploiting a cell’s own destruction machinery to tackle disease-causing proteins that have historically been highly challenging to target with conventional therapies. Yet first-generation approaches are exclusively limited to cytosolic targets, leaving extracellular and membrane-bound proteins – 40% of the human proteome – untouched.
Draupnir is extending the potential of TPD to target extracellular and membrane-bound proteins in a pioneering approach using its novel and differentiated, proprietary technology platform, utilising lysosome receptors, which holds the potential to revolutionise the field of TPD.
MP Healthcare, the corporate venture group of Mitsubishi Tanabe Pharma Corporation, and the Export and Investment Fund of Denmark (EIFO), a financing fund backed by the Danish government, join Draupnir’s existing investors, Gilde Healthcare Partners, Inkef Capital and Novo Holdings, investing a total of €12 million into the Company.
The proceeds from the financing will be used to further develop Draupnir’s risk-diversified preclinical pipeline of oral, small molecule protein degraders, which have been proven against targets that are validated and those that have been traditionally difficult to drug.
"Draupnir has a bold ambition to pioneer the next frontier of extracellular protein degradation. Our novel technology platform targeting extracellular and membrane-bound disease proteins for degradation holds great promise for targets that have previously been difficult to target with small molecules or have been undruggable, and enables the development of new therapeutic approaches for complex conditions. We are delighted to welcome MP Healthcare and the Export and Investment Fund of Denmark as investors in the Company and thank our existing investors, Gilde Healthcare Partners, Inkef Capital and Novo Holdings, for their continued support", Andrew Hotchkiss, Chief Executive Officer of Draupnir Bio.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
